Develops cytisinicline, an investigational medicine for people seeking to quit smoking or vaping.
10-K for FY2025, filed Mar 24, 2026
People seeking to quit smoking or vaping are the intended users. The company is considering sales through strategic partners, distributors, a contract sales force or its own sales infrastructure, including possible direct-to-consumer marketing.
10-K for FY2025, filed Mar 24, 2026
10-Q for Q3 FY2026, filed Nov 10, 2026
−$12.1MView ↗
8-K, filed Oct 1, 2026
On October 1, 2026, Achieve Life Sciences, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”)…View ↗
8-K, filed May 12, 2026
On May 7, 2026, Thomas King informed the Board that he has elected to resign from his position as a member and as chairman of the Board…View ↗
8-K, filed Apr 16, 2026
In connection with the private placement, the company’s board of directors has appointed Andrew D. Goldberg, MD to the position of Chief…View ↗
Vaping enters the core program
The older report described vaping as an area the company planned to add to its smoking-cessation work; the latest report describes development for both smoking and e-cigarette cessation as part of its nicotine-dependence focus.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 24, 2026We also plan to continue expanding our focus to address other methods of nicotine addiction such as e-cigarettes/vaping. The use of…View ↗
Competes with Pfizer and GlaxoSmithKline
10-K for FY2025, filed Mar 24, 2026Only two non-nicotine, prescription treatments for smoking cessation are currently available in the United States; “varenicline” (marketed…View ↗
Loading...